TARO-CARBAMAZEPINE CHEWABLE TABLETS 200 MG
CARBAMAZEPINE : 200 MG · DIN 02244404 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-CARBAMAZEPINE CHEWABLE TABLETS?
TARO-CARBAMAZEPINE CHEWABLE TABLETS 200 MG contains CARBAMAZEPINE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02244404, held by TARO PHARMACEUTICALS INC, supplied as TABLET (CHEWABLE) for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Apr-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-CARBAMAZEPINE CHEWABLE TABLETS used for?
TARO-CARBAMAZEPINE is indicated for use as an anticonvulsant drug either alone or in combination with other anticonvulsant drugs for Epilepsy. It's also indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douloureux). Additionally, it may be used as a monotherapy or as an adjunct to lithium in the treatment of acute mania or prophylaxis of bipolar (manic-depressive) disorders in patients who are resistant to or are intolerant of conventional antimanic drugs.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02244404 |
|---|---|
| Brand name | TARO-CARBAMAZEPINE CHEWABLE TABLETS |
| Generic / active ingredient | CARBAMAZEPINE : 200 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 200 MG |
| Dosage form | TABLET (CHEWABLE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AF01 CARBAMAZEPINE |
| AHFS class | 08:30.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Apr-2002 |
| Original market date | 2002-10-10 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Bottles of 100's for TARO-CARBAMAZEPINE CHEWABLE TABLETS 100 mg and 200 mg; bottles of 450 mL for TARO-CARBAMAZEPINE (suspension) 100 mg/5 mL
What can be used instead?
Other Canadian products sharing ATC code N03AF01 CARBAMAZEPINE. 11 of 46 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MINT-CARBAMAZEPINE | 200 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02541238 |
| SANDOZ-CARBAMAZEPINE CR | 200 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261839 |
| SANDOZ-CARBAMAZEPINE CR | 400 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02261847 |
| TARO-CARBAMAZEPINE | 100 MG / 5 ML | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02367394 |
| TARO-CARBAMAZEPINE CHEWABLE TABLETS | 100 MG | TABLET (CHEWABLE) | TARO PHARMACEUTICALS INC | MARKETED | DIN 02244403 |
| TEGRETOL | 200 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00010405 |
| TEGRETOL CR | 200 MG | TABLET (EXTENDED-RELEASE) | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00773611 |
| TEGRETOL CR | 400 MG | TABLET (EXTENDED-RELEASE) | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00755583 |
| TEGRETOL SUSPENSION | 100 MG / 5 ML | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02194333 |
| TEVA-CARBAMAZEPINE | 200 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00782718 |
Who else supplies CARBAMAZEPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CARBAMAZEPINE appears in 123 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.